Phase 2 study for people with Myeloma

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor AbbVie
Registry number NCT06953960
Started 23 July 2025 Today 16 October 2026 Estimated completion 1 December 2030

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Liverpool Hospital /ID# 272002 Liverpool NSW Recruiting
Calvary Mater Newcastle /ID# 272498 Waratah NSW Recruiting
St Vincent's Hospital - Melbourne /ID# 271997 Fitzroy VIC Recruiting
Epworth HealthCare /ID# 272497 Richmond VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 325

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Documented diagnosis of multiple myeloma (MM) based on standard international myeloma working group (IMWG) diagnostic criteria.

* All participants must have measurable disease per central laboratory with at least 1 of the following assessed within 28 days prior to enrollment:

* Serum M-protein \>= 0.5 g/dL (\>= 5g/L); OR

* Urine M-protein \>= 200 mg/24 hours; OR

* For participants without measurable serum and urine M-protein: Serum free light chain (sFLC) \>= 10 mg/dL (100 mg/L), provided sFLC ratio is abnormal.

* B-cell lymphoma (BCL)-2 inhibitor treatment naïve.

* t(11;14) positive status and/or BCL2 high status.

* Must have confirmed diagnosis of relapsed or refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen, based on the investigator's determination of the international myeloma working group (IMWG) 2016 criteria.

Exclusion Criteria:

* Major surgery within 4 weeks of study treatment or planned during study participation.

* Recent infection requiring systemic treatment that was completed \<= 14 days before first dose of study treatment and/or uncontrolled active systemic infection.

Dates on the record

Started 23 July 2025
Estimated completion 1 December 2030
Registry last updated 14 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 14 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.